Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether P...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779575/ |